A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
for Systemic Lupus Erythematosus (With and Without Nephritis)
Sites in Chicago +15 more locations
Sponsor: Allogene Therapeutics
Sex: All·Age: 18 - 74
Code: NCT07085104·Phase 1·Recruiting·Listed Jul 2025